1). Vande Walle L, Van Opdenbosch N, Jacques P, Fossoul A, Verheugen E, Vogel P, et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature. 2014; 512:69–73.
Article
2). Manzoor Z, Koo JE, Koh YS. Mitogen-activated Protein Kinases Signaling in Inflammation-related Carcinogenesis. J Bacteriol Virol. 2014; 44:297–304.
3). Manzoor Z, Koh YS. Mitogen-activated Protein Kinases in Inflammation. J Bacteriol Virol. 2012; 42:189–95.
Article
4). Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002; 10:417–26.
5). Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 2004; 5:1052–60.
Article
6). Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science. 2000; 289:2350–4.
Article
7). Vereecke L, Beyaert R, Van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009; 30:383–91.
Article